Background Remdesivir is an RNA polymerase inhibitor with potent antiviral activity in vitro
and efficacy in animal models of coronavirus disease 2019 (Covid-19). Methods We …

Importance Remdesivir demonstrated clinical benefit in a placebo-controlled trial in patients
with severe coronavirus disease 2019 (COVID-19), but its effect in patients with moderate …

Background Data on the effect of initial combination therapy with ambrisentan and tadalafil
on long-term outcomes in patients with pulmonary arterial hypertension are scarce. Methods …

Background Patients with connective tissue disease-associated pulmonary arterial
hypertension (CTD-PAH), in particular systemic sclerosis (SSc), had an attenuated response …

… Ms Blair is an employee of and has investment holdings with Gilead Sciences Inc. Mr Despain
is a former employee of and has investment holdings with Gilead Sciences Inc. Dr Dufton …

In translational models of pulmonary arterial hypertension (PAH), spironolactone improves
cardiopulmonary hemodynamics by attenuating the adverse effects of hyperaldosteronism on …

BACKGROUND The purpose of this study was to compare patients with pulmonary arterial
hypertension enrolled in the AMBITION trial with (excluded from the primary analysis set [ex-…

Marburg virus (MARV) is a filovirus with documented human case-fatality rates of up to 90%.
Here, we evaluated the therapeutic efficacy of remdesivir (GS-5734) in nonhuman primates …

Background In treatment-naive patients with pulmonary arterial hypertension, initial
combination therapy with ambrisentan and tadalafil reduces the risk of clinical failure events …

Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disorder, with an
overall prevalence of at least 1:500 in the adult population although only a fraction of …